Physician profile
Eric James Smith
NPI 1790206829
$7,273.45
in general payments reported to CMS, 2019-2025
31 companies · $1,958 in 2025
The $1,958 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $105 · 2021: $387 · 2022: $1,263 · 2023: $1,667 · 2024: $1,393 · 2025: $1,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,871 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,871.44 |
| Education | $147.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,604.80 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $749.97 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $655.24 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $578.34 | 2020-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $559.97 | 2019-2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $504.48 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $327.31 | 2021-2025 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $326.29 | 2021-2023 | Belsomra |
| Axsome Therapeutics, INC. | $273.94 | 2023-2025 | Auvelity, Sunosi |
| Abbvie INC. | $264.98 | 2023-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $196.68 | 2020-2025 | Trintellix |
| Corium, LLC | $187.16 | 2022-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $176.24 | 2024-2025 | Cobenfy |
| Sage Therapeutics, LLC | $145.02 | 2024-2025 | Zurzuvae |
| Sunovion Pharmaceuticals INC. | $120.90 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $115.94 | 2020-2025 | Rexulti |
| Novo Nordisk INC | $89.18 | 2023-2025 | Wegovy, Saxenda |
| Supernus Pharmaceuticals, INC. | $68.36 | 2022-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $66.06 | 2024 | |
| Idorsia Pharmaceuticals US INC | $44.45 | 2023-2024 | Quviviq |
| Tris Pharma INC | $32.04 | 2021 | |
| Collegium Pharmaceutical, INC. | $24.65 | 2025 | Jornay Pm |
| Indivior INC. | $23.05 | 2022 | |
| Noven Therapeutics, LLC | $22.52 | 2024 | Xelstrym, Secuado |
| Neos Therapeutics, Lp | $21.16 | 2023 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $20.41 | 2022 | |
| Genentech USA, INC. | $17.93 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.23 | 2019 | |
| Shire North American Group INC | $14.23 | 2019 | |
| Bioxcel Therapeutics, INC. | $13.80 | 2023 | Igalmi |
| Novartis Pharmaceuticals Corporation | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.